Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/138214
DC FieldValue
dc.titleCD137L- DENDRITIC CELLS HAVE A NOVEL INFLAMMATORY PHENOTYPE AND INDUCE A POTENT TC1 RESPONSE AGAINST EPSTEIN-BARR VIRUS
dc.contributor.authorBHUSHAN DHARMADHIKARI
dc.date.accessioned2017-12-31T18:01:40Z
dc.date.available2017-12-31T18:01:40Z
dc.date.issued2017-04-28
dc.identifier.citationBHUSHAN DHARMADHIKARI (2017-04-28). CD137L- DENDRITIC CELLS HAVE A NOVEL INFLAMMATORY PHENOTYPE AND INDUCE A POTENT TC1 RESPONSE AGAINST EPSTEIN-BARR VIRUS. ScholarBank@NUS Repository.
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/138214
dc.description.abstractMost clinical studies with dendritic cells (DCs) as anti-cancer vaccines have relied on GM-CSF + IL-4 derived cDCs. Although proven to be safe, the overall clinical benefits are low. These disappointing results are largely due the inability of cDCs to mount sufficiently strong T cell responses. In this study, we show that CD137L-DCs, generated via CD137L signaling, have a novel inflammatory phenotype and are closely related to in-vivo DCs. CD137L-DCs induce more potent CD8+ T cell response against cancer-associated Epstein-Barr virus and enhance the physiological of fitness of T cells. We thus report, CD137L-DCs as the next generation DCs for DC based immunotherapy. A phase I trial for treatment of Nasopharyngeal carcinoma (NCT03282617) is currently underway.
dc.language.isoen
dc.subjectDendritic cells, CD137 ligand, Immunotherapy, Cancer
dc.typeThesis
dc.contributor.departmentPHYSIOLOGY
dc.contributor.supervisorSCHWARZ, HERBERT
dc.description.degreePh.D
dc.description.degreeconferredDOCTOR OF PHILOSOPHY
Appears in Collections:Ph.D Theses (Open)

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Dharmadhikari B.pdf2.17 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

124
checked on Feb 2, 2023

Download(s)

168
checked on Feb 2, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.